Llusern Scientific was born from a shared desire to make a difference. Our point-of-care testing technology consists of a unique swabbing method, a one-tube molecular LAMP reaction and a user-friendly, affordable, portable electronic reader device. Our technology was originally developed for the diagnosis of Urinary Tract Infections (UTIs) but we responded to need during the COVID-19 pandemic and our first product on the market is a test for the accurate detection of SARS-CoV-2.

Our Story

Llusern’s co-founders all met while working at the University of South Wales. The story began back in 2016 when the team received seed funding from the Longitude Prize for their work on UTIs. Between them, they have over 50 years experience in molecular biology, microbiology and biomedical engineering. Our story continues to unfold… follow our journey here.

Our Vision

Our vision is to be a part of the change to a world where anyone, anywhere has access to accurate diagnostic testing and appropriate treatment. No-one should die from a preventable disease.

Our Mission

Our mission is to reduce existing barriers to accurate diagnostic tools – working with our partners to bring diagnostic testing out of the highly specialised lab environment and truly to point-of-care – in any environment

Core Team

Dr Jeroen Nieuwland

Co-founder

Dr Emma Hayhurst

Co-founder

Dr Ali Roula

Co-founder

Advisory Board

Mark Helmich

Mark Helmich is  Managing Director at GX Group

Deborah

Deborah Komianos

Regional Director and Veterinary Surgeon at CVS (UK) Ltd.

Nanette

Nanette Bartram

Biotechnology and diagnostic consultant at BIC Innovation Ltd

If you have an enquiry about one of our products or anything else, please don't hesitate to contact us